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Abstract
Background: The erbB receptors and their ligands are involved in the pathogenesis and progression of oral
squamous cell carcinoma (OSCC). Although EGFR and Her-2 are frequently overexpressed in OSCC, few studies
evaluated these proteins in saliva and their association with the tumor, which may represent potential usefulness
in a clinical setting.
Methods: The levels of EGFR, Her-2, and EGF were evaluated in saliva of 46 patients with OSCC before and after
the surgical removal of the lesion, as well as in matched healthy controls. The relationship of salivary levels and
EGFR and Her-2 immunoexpression in tumor samples with clinicopathological features was analyzed.
Results: EGFR and Her-2 salivary levels did not show difference between to pre-surgery and control groups,
however, both demonstrated an increase after surgical removal of the tumor. No association was detectable
among receptor salivary levels, tissue expression and clinicopathological features. EGF levels in pre-surgery group
were significantly lower when compared to the control group.
Conclusions: EGFR and Her-2 were not considered to be valuable salivary tumor markers in OSCC, however, lower
levels of EGF in saliva may suggest a higher susceptibility for OSCC development.
Background
The epidermal growth factor family of transmembrane
tyrosine kinase receptors (erbB receptors) includes four
receptors: the epidermal growth factor receptor (EGFR,
c-erbB-1, Her-1), c-erbB-2 (Her-2), c-erbB-3 (Her-3),
and c-erbB-4 (Her-4) [1,2]. Ligand binding to the erbB
receptors leads to the transcription of genes responsible
for the inhibition of apoptosis, cell growth, angiogenesis,
cell adhesion, cell motility, and invasion, and enhances
the malignant potential of epithelial tissues, which in
turn overexpress erbB receptors [1,2].
It has been reported that OSCCs present an increase
of 42% to 58% in EGFR [3] and 3% to 41% in Her-2
expression [4]. Immunohistochemical staining has been
the most common method used to detect overexpres-
sion of erbB receptors, however, since its extracelular
receptor domain (ECD) can be proteolytically released
from the cell surface, this raises the possibility of using
serum ECD antigens as diagnostic marker in patient
with EGFR and Her-2 overexpressing tumors [5]. How-
ever, thenumber of publications that analyzed the levels
of erbB receptors in human serum, plasma, or saliva
samples is rather small, and the comparison of the pub-
lished data reveals a great disparity [5,6].
Some studies point toward the need for the simulta-
neous inclusion of EGF (epidermal growth factor)
assessment when analyzing EGF receptors [7]. EGF
modulates the growth and differentiation of various can-
cer cells, as well as normal epithelial cells, and is
excreted through human saliva [7,8]. In fact, EGF has
been shown to enhance the cell growth of bladder, lung,
breast, and colon cancer [8,9].
This study aimed to explore the expression of EGFR,
Her-2, and EGF in OSCC. The levels of these proteins
in the saliva of patients with OSCC were determined at
the moment of diagnosis and six weeks after the surgical
removal of the lesion and then compared to healthy
matched donors. The immunoexpression of EGFR and
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Her-2 in tumor samples was evaluated and correlated
with the salivary levels of these proteins and the clinico-
pathological features of the tumors.
Methods
The protocol of this study was approved by the
Research Ethics Committee from Universidade Federal
de Minas Gerais, and a signed informed consent was
obtained from all the participants.
Subjects
Patients with a histopathological diagnosis of OSCC
were enrolled in the research. Clinical data, such as age,
gender, symptoms, location of the tumor, TNM, and
tobacco and alcohol habits were obtained from medical
records. The saliva was collected at the moment of diag-
nosis and six weeks after the surgical removal of the
tumor.
The control group included healthy individuals with-
out oral lesions and who had been matched by age, sex,
and tobacco usage [10].
Patients and controls who showed signs of significant
morbidity or active medical problems, such as conges-
tive heart failure, active infection, autoimmune disease,
hepatitis, HIV, or abnormal renal function, were
excluded from the study.
Saliva and tumor samples
Subjects were refrained from eating, drinking, smok-
ing, or oral hygiene procedures for at least 1 hour
prior to saliva collection. The whole saliva sample
was collected for a 5-minute period using a cotton
wool swab inserted in the mouth (Salivette®, Sarstedt
AG & Co., Nümbrecht, Oberbergischer Kreis, Ger-
many). The saliva sample was subsequently diluted
(1:1) in a PBS solution containing protease inhibitors
(0.1 mM PMSF, 0.1 mM benzethonium chloride, 10
mM EDTA, and 0.01 mg/mL aprotinin A) and 0.05%
Tween-20 and was stored at -20°C until analysis. Sec-
tions of formalin-fixed, paraffin-embedded incisional
biopsy specimens of the tumor were evaluated by
H&E staining and used for immunohistochemistry.
The histological grade of malignancy was performed
employing two parameters of a recognized grading
system: degree of keratinization and nuclear pleo-
morphism [11].
ELISA
Salivary protein levels were measured by sandwich
ELISA, in accordance with the procedures recom-
mended by the manufacturers. The following kits were
used: Epidermal Growth Factor Receptor (CBA 018) and
c-erbB2/c-neu Rapid Format ELISA kit (QIA10), both
from Calbiochem® (Darmstadt, Hessen, Germany) and
Human EGF (DuoSet, R&D Systems, Minneapolis, MN,
USA).
The total protein content in the saliva was determined
using the Bradford method [12] (Sigma, Saint Louis,
MO, USA) according to the BSA standard (Fermentas
Life Sciences, Vilnius, Lithuania). The total protein con-
tent was used to normalize the EGF, EGFR, and Her-2
values for each sample.
Immunohistochemistry (IHC)
IHC reactions for the detection of EGFR and Her-2
antigens were performed using the monoclonal anti-
bodies clone 31G7 (Zymed Laboratories Inc., San Fran-
cisco, CA, USA) and clone CB11 (Novocastra
Laboratories, Newcastle upon Tyne, UK), respectively.
Sections of oral mucosa and breast carcinoma were used
as EGFR and Her-2 positive controls, respectively.
Evaluation of IHC
EGFR expression was evaluated on the basis of
extent and intensity of immunolabeling in tumor cell
membranes, classified on a four-point scale: 0 (no
labeling, or labeling in < 10% of tumor cells); 1
(weak labeling, homogeneous or patchy, in > 10% of
the tumor cells); 2 (moderate labeling, homogeneous
or patchy, in > 10% of the tumor cells); 3 (intense
labeling, homogeneous or patchy, in > 10% of the
tumor cells). These scores were subsequently
grouped into two categories: negative (0 or 1) and
positive labeling (2 or 3) [13].
The Her-2 protein immunoexpression was analyzed
using the American Society of Clinical Oncology/College
of American Pathologists (ASCO/CAP) guidelines for
Her-2 testing in breast cancer (0, no staining or mem-
brane staining is observed in < 10% of the tumor cells;
1+, faint/barely perceivable membrane staining is
detected in > 10% of the tumor cells, and only part of
the membrane is stained; 2+, weak to moderate com-
plete membrane staining is observed in > 10% of the
tumor cells; 3+, strong complete membrane staining is
observed in > 30% of the tumor cells). Data were cate-
gorized as negative or positive expression [14].
Statistical analysis
SPSS (Statistic Package for Social Sciences) 12.0 for Win-
dows (SPSS Inc., Chicago, IL, USA) and Graph Pad Prism
4 were used to analyze the data. Results were expressed
as mean ± standard deviation. The Mann Whitney test
was used to compare the salivary levels between cases
and controls, while the Wilcoxon test was used to com-
pare levels in OSCC patients before and after surgery.
The categorical variables were analyzed using the chi-
square test. The differences between the values of the
groups were considered significant at p < 0.05.
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Results
Patient information and clinicopathological and immuno-
histochemical data are shown in table 1. The sample con-
sisted of 46 patients with OSCC in varied locations and
46 healthy matched volunteers as the control group (32
male, 14 female). The T-staging and N-staging of the
tumors were described according to AJCC (American
Joint Committee on Cancer)/UICC (International Union
Against Cancer) classification for oral cavity carcinomas
[15].
The mean of ages were 55.2 years (range from 16 to
80) and 54.8 years (range from 16 to 86) for the case
and control groups, respectively. The tongue and/or
floor of the mouth were the most common tumor sites,
representing 78.3% of the cases. Eleven (23.9%) patients
died from the disease or due to complications during
the treatment before completing the period of six weeks
after surgery, thus the post-surgery group consisted of
22 individuals. The treatment consisted of surgery fol-
lowed by postoperative radiotherapy in 16 cases (72.7%),
only surgery in 5 cases (22.7%), and surgery together
with postoperative radiotherapy plus chemotherapy in
one patient (4.6%).
Fourteen tumors were graded as well differentiated
(30.4%), 14 moderately differentiated (30.4%), and 18
poorly differentiated (39.2%). The EGFR immunohisto-
chemical expression was considered positive in 23 (50%)
cases (Figure 1a), while 23 tumors (50%) proved to be
negative (Table 1). The well differentiated tumors were
more frequently positive for EGFR than were the others
(p < 0.05) The Her-2 protein expression was found to
be negative in 45 (97.8%) cases (Table 1) (Figure 1b).
Salivary levels of EGFR, Her-2, and EGF are repre-
sented in figure 2a, b, c. EGFR and Her-2 salivary levels
did not show difference between to pre-surgery and
control groups. The measures 6 weeks after surgery
showed a significant increase of EGFR and Her-2 (p <
0.05). The salivary levels of EGF in the pre-surgery
group, as compared to the control group, were signifi-
cantly lower. A tendency toward an increase in EGF
levels after surgery as regards the pre-surgery and con-
trol groups could be observed, but the difference was
not statistically significant (p > 0.05). The EGF/EGFR
ratio in the pre-surgery group (0.09 ± 0.05) was signifi-
cantly lower than that in the control group (0.12 ±
0.05). The post-surgery group presented a significantly
higher ratio (2.88 ± 15.74) in relation to the pre-surgery
group (p < 0.05) and showed a trend towards a higher
ratio when compared to the control (p = 0.057). The
EGF/Her-2 ratio presented significant differences when
comparing the post-surgery group (29.49 ± 193.67) to
the control group (1.91 ± 1.48) and the post-surgery
group to the pre-surgery group (1.74 ± 1.27) (p < 0.05).
There was no significant association between EGFR,
Her-2, and EGF salivary levels and the immunoexpres-
sion of the proteins EGFR and Her-2 in tumor speci-
mens (p > 0.05). The salivary levels of the proteins were
not associated with clinicopathological features, such as
patient age, smoking habit, site, histological grading,
T status, or nodal involvement of the tumor (p > 0.05).
Discussion
An increased attention has been focused on the role of
growth factors and their receptors in pathogenesis of
HNSCC (head and neck squamous cell carcinoma) and
as potencial targets for new therapies [16-18]. In the
present study, EGFR overexpression was found in 50%
of OSCC, while 97.8% of the tumor specimens were
negative for Her-2. Although EGFR overexpression has
Figure 1 Immunoexpression of EGFR and Her-2. a: positive
immunoexpression of EGFR in OSCC (400×); b: negative expression
of Her-2 in OSCC (400×).
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1 60/M Tongue Well T3-T4 Positive Positive Negative NED
2 60/M Floor of
mouth
Moderately T3-T4 Positive Negative Negative DOD
3 47/M Tongue Poorly T3-T4 Positive Positive Negative NED
4 55/M Tongue Well T3-T4 Positive Positive Negative DOD
5 43/M Tongue Poorly T3-T4 Positive Positive Negative DOD
6 36/M Tongue Well T3-T4 Positive Positive Negative DOD
7 55/M Tongue Moderately T3-T4 Positive Negative Negative NED
8 44/F Floor of
mouth
Poorly T1-T2 Positive Positive Negative NED
9 63/M Tongue Poorly T1-T2 Positive Positive Negative NED
10 50/M Tongue Poorly T3-T4 Positive Negative Negative NED
11 55/M Floor of
mouth
Moderately T1-T2 Negative Positive Negative NED
12 74/M Floor of
mouth
Poorly T3-T4 Positive Negative Negative DOD
13 58/M Floor of
mouth
Moderately T3-T4 Negative Negative Negative DOD
14 40/F Floor of
mouth
Poorly T1-T2 Negative Negative Negative NED
15 57/F Tongue Moderately T1-T2 NA Negative Negative NED
16 56/F Floor of
mouth
Poorly T3-T4 Positive Negative Negative NED
17 44/M Floor of
mouth
Well T3-T4 Negative Negative Negative NED
18 62/M Floor of
mouth
Well T1-T2 Negative Positive Negative NED
19 50/M Floor of
mouth
Moderately T3-T4 Positive Negative Negative NED
20 54/M Tongue Well T3-T4 Positive Positive Negative NED
21 79/F Tongue Well T1-T2 Negative Positive Negative NED
22 48/M Tongue Moderately T1-T2 Negative Negative Negative NED
23 16/F Tongue Moderately T1-T2 Positive Negative Negative NED
24 49/M Floor of
mouth
Poorly T3-T4 Positive Negative Negative NED
25 80/M Floor of
mouth
Poorly T1-T2 Negative Negative Negative NED
26 62/M Floor of
mouth
Poorly T1-T2 Negative Negative Negative NED
27 72/F Tongue Well T1-T2 Positive Positive Negative NED
28 78/F Tongue Well T1-T2 Negative Positive Negative NED
29 72/F Tongue Poorly T1-T2 Positive Negative Negative DOD
30 48/M Tongue Poorly T3-T4 Positive Negative Negative NED
31 52/F Tongue Poorly T1-T2 Positive Negative Negative NED
32 46/M Tongue Poorly T3-T4 Positive Negative Positive NED
33 61/M Tongue Poorly T3-T4 Positive Negative Negative NED
34 69/M Floor of
mouth
Poorly T3-T4 Positive Positive Negative NED
35 53/M Tongue Well T1-T2 Positive Positive Negative NED
36 52/M Tongue Well T1-T2 Positive Positive Negative NED
37 35/F Palate Well T1-T2 Negative Positive Negative NED
38 80/F Gingiva Moderately T1-T2 Negative Negative Negative DOD
39 62/F Gingiva Well T1-T2 Negative Negative Negative DOD
40 44/M Palate Poorly T3-T4 Positive Positive Negative NED
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been reported to be a hallmark of OSCC [5,19,20],
investigations on Her-2 in OSCC have described protein
overexpression in a very few tumour specimens, which
did not appear to be of prognostic relevance
[5,17,21,22].
Some studies have reported an association between the
overexpression of EGFR and poor tumor differentiation in
OSCC [20]. Conversely, our results demonstrated an
increase of EGFR expression in well differentiated tumors,
as has been reported in prior literature [23]. A possible
explanation is that this receptor may be related to the
degree of differentiation of neoplastic keratinocytes [23].
In the present study, salivary EGFR and Her-2 levels
were not elevated in patients with OSCC. Moreover, no
significant association was found between the salivary
levels of the proteins and clinicopathological data, such
as patient age, smoking habit, site, histological grading,
T status, or nodal involvement of the tumor and most
notably, no diferences in salivary levels could be
observed in patients with immunohistochemically posi-
tive nor negative tumors. In a similar study evaluating
breast cancer [24], the authors found no association
between the levels of Her-2 in the serum and those in
the tumor. While the activation of EGFR and Her-2 on
the cell surface of the head and neck tumors has proven
to lead to tumor growth, these are not necessarily
expressed in altered levels, nor released into the saliva
of OSCC patients. It is also important to consider that
epithelial tumours present different capacities to shed
EGFR and Her-2 ECD from the cell membrane to saliva
or to metabolize these proteins [25]. In addition, certain
factors not related to the cancer may influence the Her-
2 ECD levels, such as hormones, nonmalignant hepatic
disorders and others [6,26,27]. Finally, some studies
have suggested that protein levels in the serum, as com-
pared to those in the tissue, tend to be lower. The
authors associated the results with the methods used to
determine cut-off points in the serum, as compared to
those in the tissue (usually through immunohistochem-
ical staining using visual analysis) [28].
EGFR and Her-2 showed elevated levels after surgical
removal. The increased ratio of EGF/EGFR and EGF/
Her-2 in post-surgery patients may reflect the role of
EGF and metaloproteinases in healing [29]. In addition,
the metaloproteinases (MMPs), responsible for the
degradation of the extracellular matrix and remodeling,
are also involved in the release of ECD, whereas the
increased levels of EGFR, Her-2, and EGF after the
removal of the tumor may be indicative of up-regulated
MMP activity during healing [30].
The salivary levels of EGF in the pre-surgery group,
as compared to the control group, were significantly
lower. EGF is the major ligand for EGFR and a mito-
genic factor which stimulates the cell division of
various tissues and plays an important role in main-
taining the anatomic continuity of the oral cavity’s
mucous membrane [7]. The low concentration of EGF
in cancer patients observed in this study is in agree-
ment with previous data concerning the serum of
thyroid carcinoma [31]. Our results from pre-surgery
patients suggest that the impaired ability to heal oral
mucosa damage in neoplastic diseases may be related
to the low EGF concentration in the saliva [32-34].
Another hypothesis to explain the lower concentration
of EGF in the saliva of patients with OSCC may be
the correlation between the EGF and ligands compet-
ing for EGFR [7]. Therefore, it is suggested that the
lower EGF/EGFR ratio in OSCC patients, as compared
to the controls, observed in this study may represent a
higher receptor-ligand affinity due to the tumoral pro-
cess [33]. Expression of a high number of receptors or
truncated receptors on the surface of tumor cells can
increase the sensitivity to low concentrations of host-
or tumor-derived growth factors [32].
Conclusions
These findings suggest that the use of EGFR and Her-2
as salivary markers of OSCC is not recommended
because no significant preoperative elevation and no
association to clinicopathological features were found.
The lower EGF concentration in the saliva of pre-sur-
gery patients and its growing tendency after surgery
may suggest an important role for this factor in oral
cavity carcinoma development as well as in the healing
of oral mucosa. Further studies are needed due to the
complexity of the system at the receptor and ligand
levels and the integrated biological functions of the erbB
family in oral squamous cell carcinomas.
Table 1: Clinicopathological features of patients with oral squamous cell carcinoma (Continued)
41 53/F Labial mucosa Well T1-T2 Positive Positive Negative NED
42 63/M Gingiva Moderately T3-T4 Negative Positive Negative NED
43 45/M Palate Moderately T3-T4 Positive Positive Negative DOD
44 48/M Palate Moderately T3-T4 Positive Positive Negative NED
45 64/M Palate Moderately T3-T4 Positive Positive Negative NED
46 48/M Gingiva Moderately T3-T4 Positive Negative Negative DOD
aM: male, F: female, NA: not available; NED: no evidence of disease, DOD: dead of disease
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Figure 2 Salivary levels of EGFR, Her-2 and EGF. a: Salivary levels with standard deviation of EGFR in the control and OSCC groups; b: salivary
levels with standard deviation of Her -2 in the control and OSCC groups; c: salivary levels with standard deviation of EGF in the control and
OSCC groups. OSCC: oral squamous cell carcinoma; Pre-S: pre-surgery; Post-S: post-surgery; *:OSCC vs. control group (p < 0.05); #: pre-surgery vs.
post-surgery (p < 0.05).
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